News
EQS-News: SARTORIUS AG: Resolutions of the Annual General Meeting of Sartorius AG
EQS-News: SARTORIUS AG: Resolutions of the Annual General Meeting of Sartorius AG
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry
EQS-News: Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry
EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year
EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: Biotest AG: Biotest core business profitable at Euro 60.7 million
EQS-News: Biotest AG: Biotest core business profitable at Euro 60.7 million
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Manitoba Becomes a Provincial Trailblazer in Providing Simplified Access to Advanced Glucose Monitors
Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced that its Dexcom G6 CGM System will be available to people of all
EQS-News: Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023
EQS-News: Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Waters stellt die nächste Generation des HPLC-Systems Alliance iS vor, das die Zahl der üblichen Laborfehler um bis zu 40 % reduzieren soll
PITTCON 2023 – Die Waters Corporation (NYSE:WAT) stellte heute mit Alliance iS ihr intelligentes HPLC-System der nächsten Generation vor. Es wurde entwickelt, um Compliance-Risiken durch neue
Die neue Battery Cycler Microcalorimeter Solution von Waters beschleunigt Praxistests von Monaten auf Wochen
PITTCON 2023 — Die Waters Corporation (NYSE:WAT) kündigte heute eine neue Battery Cycler Microcalorimeter Solution ihrer TA Instruments™ Division an, die eine hochauflösende Charakterisierung von
Waters’ New Battery Cycler Microcalorimeter Solution Accelerates Real-World Testing from Months to Weeks
PITTCON 2023 — Waters Corporation (NYSE:WAT) today announced a new Battery Cycler Microcalorimeter Solution from its TA Instruments™ Division for high-resolution characterization of battery cells
Waters Introduces Next-Generation Alliance iS HPLC System Aimed at Reducing Up to 40% of Common Lab Errors
PITTCON 2023 – Waters Corporation (NYSE:WAT) today introduced Alliance iS, the next-generation intelligent HPLC System, designed to reduce compliance risk by adding new levels of proactive error
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
AEVIS VICTORIA SA – Consolidated EBITDA 2022 up by more than 60% to between CHF 125 and 130 million (2021: CHF 78.4m); net profit 2022 will exceed CHF 60 million (2021: CHF 4.6m)
AEVIS VICTORIA SA – Consolidated EBITDA 2022 up by more than 60% to between CHF 125 and 130 million (2021: CHF 78.4m); net profit 2022 will exceed CHF 60 million (2021: CHF 4.6m)
EQS-News: Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
EQS-News: Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia